TATVA Stock Overview
Engages in manufacture and sale of specialty chemicals in India and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 1/6 |
Tatva Chintan Pharma Chem Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,026.75 |
| 52 Week High | ₹1,650.85 |
| 52 Week Low | ₹932.25 |
| Beta | -0.075 |
| 11 Month Change | 3.70% |
| 3 Month Change | -7.07% |
| 1 Year Change | -35.13% |
| 33 Year Change | -52.35% |
| 5 Year Change | n/a |
| Change since IPO | -55.59% |
Recent News & Updates
Tatva Chintan Pharma Chem Limited's (NSE:TATVA) Price In Tune With Revenues
Sep 26
Tatva Chintan Pharma Chem (NSE:TATVA) Has Affirmed Its Dividend Of ₹2.00
Aug 29Earnings Report: Tatva Chintan Pharma Chem Limited Missed Revenue Estimates By 33%
Jul 27Recent updates
Tatva Chintan Pharma Chem Limited's (NSE:TATVA) Price In Tune With Revenues
Sep 26Tatva Chintan Pharma Chem (NSE:TATVA) Has Affirmed Its Dividend Of ₹2.00
Aug 29Earnings Report: Tatva Chintan Pharma Chem Limited Missed Revenue Estimates By 33%
Jul 27Weak Statutory Earnings May Not Tell The Whole Story For Tatva Chintan Pharma Chem (NSE:TATVA)
May 11Tatva Chintan Pharma Chem Limited's (NSE:TATVA) Share Price Matching Investor Opinion
Apr 04These Analysts Just Made A Notable Downgrade To Their Tatva Chintan Pharma Chem Limited (NSE:TATVA) EPS Forecasts
Jan 26Tatva Chintan Pharma Chem Limited (NSE:TATVA) Analysts Are Reducing Their Forecasts For This Year
May 10Tatva Chintan Pharma Chem Limited Just Missed Revenue By 15%: Here's What Analysts Think Will Happen Next
Jul 28Getting In Cheap On Tatva Chintan Pharma Chem Limited (NSE:TATVA) Is Unlikely
Jun 17Investors Shouldn't Be Too Comfortable With Tatva Chintan Pharma Chem's (NSE:TATVA) Robust Earnings
May 03Are Investors Undervaluing Tatva Chintan Pharma Chem Limited (NSE:TATVA) By 45%?
Dec 06Shareholder Returns
| TATVA | IN Chemicals | IN Market | |
|---|---|---|---|
| 7D | 4.0% | 0.7% | 2.5% |
| 1Y | -35.1% | 28.4% | 46.3% |
Return vs Industry: TATVA underperformed the Indian Chemicals industry which returned 28.4% over the past year.
Return vs Market: TATVA underperformed the Indian Market which returned 46.3% over the past year.
Price Volatility
| TATVA volatility | |
|---|---|
| TATVA Average Weekly Movement | 4.5% |
| Chemicals Industry Average Movement | 5.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.3% |
| 10% least volatile stocks in IN Market | 3.9% |
Stable Share Price: TATVA has not had significant price volatility in the past 3 months.
Volatility Over Time: TATVA's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 689 | Chintan Shah | www.tatvachintan.com |
Tatva Chintan Pharma Chem Limited engages in manufacture and sale of specialty chemicals in India and internationally. It offers a portfolio of structure directing agents for zeolites synthesis; phase transfer catalysts; electrolyte salts for super capacitor and zinc ion batteries; and pharmaceutical and agrochemical products, and other specialty chemicals in the form of intermediates, disinfectants, catalysts, and solvents. The company serves automotive, refinery, pharmaceutical, agro-chemicals, paints and coatings, dyes and pigments, personal care, and flavor and fragrances industries.
Tatva Chintan Pharma Chem Limited Fundamentals Summary
| TATVA fundamental statistics | |
|---|---|
| Market cap | ₹24.09b |
| Earnings (TTM) | ₹260.59m |
| Revenue (TTM) | ₹3.85b |
92.2x
P/E Ratio6.2x
P/S RatioIs TATVA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TATVA income statement (TTM) | |
|---|---|
| Revenue | ₹3.85b |
| Cost of Revenue | ₹1.73b |
| Gross Profit | ₹2.11b |
| Other Expenses | ₹1.85b |
| Earnings | ₹260.59m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 11.14 |
| Gross Margin | 54.98% |
| Net Profit Margin | 6.78% |
| Debt/Equity Ratio | 1.9% |
How did TATVA perform over the long term?
See historical performance and comparison